๐Ÿงฌ Biotech Catalyst Calendar

Updated daily ยท catalystalert.io + dansfera.com Admin
421
Upcoming
12
This Month
409
Trial Readouts
11
PDUFA Dates
1
AdCom Votes
Type: All ๐Ÿ”ฌ Trial ๐Ÿ’Š PDUFA ๐Ÿ›๏ธ AdCom ๐Ÿ“Š Earnings
Mkt Size: All โ‰ฅ$1B โ‰ฅ$5B โ‰ฅ$10B โ‰ฅ$50B
Date Ticker Company Drug Type Phase PoA Mkt Size Notes
2026-04-29
in 1 days 		VRNA VERONA PHARMA Glycopyrrolate 21.25 mcg Trial Phase 2 โ€” $15B Primary completion for Glycopyrrolate 21.25 mcg trial (NCT07016412) in Chronic Obstructive
2026-04-29
in 1 days 		VRNA VERONA PHARMA Ensifentrine 3 mg Trial Phase 2 โ€” $15B Primary completion for Ensifentrine 3 mg trial (NCT07016412) in Chronic Obstructive Pulmon
2026-04-30
in 2 days 		AZN AstraZeneca HR+/HER2- advanced breast cancer โ€” first-line with emergent ESR1 mutation camizestrant (NDA 220359 AdCom โ€” 85% $12B APR 30 2026 2 days ๐Ÿ›๏ธ AdCom (camizestrant (NDA 220359)) $AZN AstraZeneca HR+/HER2- advance
2026-04-30
in 2 days 		NVS Novartis AG Remibrutinib Trial Phase 3 โ€” $12B Primary completion for Remibrutinib trial (NCT05156281) in Relapsing Multiple Sclerosis
2026-04-30
in 2 days 		RHHBY Roche Holding AG Rituximab Trial Phase 3 โ€” $25B Primary completion for Rituximab trial (NCT03274492) in Diffuse Large B-Cell Lymphoma
2026-04-30
in 2 days 		RHHBY Roche Holding AG Prednisone Trial Phase 3 โ€” $15B Primary completion for Prednisone trial (NCT03274492) in Diffuse Large B-Cell Lymphoma
2026-04-30
in 2 days 		RHHBY Roche Holding AG Cyclophosphamide Trial Phase 3 โ€” $18B Primary completion for Cyclophosphamide trial (NCT03274492) in Diffuse Large B-Cell Lympho
2026-04-30
in 2 days 		DNLI Denali Therapeutics Inc. BIIB122 225 mg Trial Phase 2 โ€” $12B Primary completion for BIIB122 225 mg trial (NCT06602193) in Parkinson Disease
2026-04-30
in 2 days 		ANRO Alto Neuroscience, Inc. DR30206 Trial Phase 2 โ€” $15B Primary completion for DR30206 trial (NCT07056777) in Gastrointestinal Cancer
2026-04-30
in 2 days 		AZNCF ASTRAZENECA PLC Tozorakimab Trial Phase 3 โ€” $20B Primary completion for Tozorakimab trial (NCT06897748) in Chronic Obstructive Pulmonary Di
2026-04-30
in 2 days 		PFE PFIZER vepdegestrant Trial Phase 2 โ€” $18B Primary completion for vepdegestrant trial (NCT06125522) in Breast Cancer
2026-04-30
in 2 days 		PFE PFIZER Samuraciclib Trial Phase 2 โ€” $18B Primary completion for Samuraciclib trial (NCT06125522) in Breast Cancer
2026-05-05
in 77 days 		BNTX BioNTech SE BNT162b2 (Omi LP.8.1) Trial Phase 3 โ€” $15B Primary completion for BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) trial (NCT070693
2026-05-08
in 80 days 		AZN AstraZeneca PLC AZD3470 Trial Phase 2 โ€” $15B Primary completion for AZD3470 trial (NCT06137144) in Lymphoma
2026-05-13
in 85 days 		REGN Regeneron Pharmaceuticals, Inc. Pemetrexed Trial Phase 3 โ€” $15B Primary completion for Pemetrexed trial (NCT06161441) in Resectable Non-small Cell Lung Ca
2026-05-14
in 86 days 		BIIB Biogen Inc. BIIB080 Trial Phase 2 โ€” $15B Primary completion for BIIB080 trial (NCT05399888) in Mild Cognitive Impairment Due to Alz
2026-05-15
in 87 days 		NMRA Neumora Therapeutics, Inc. NMRA-335140 Trial Phase 3 โ€” $15B Primary completion for NMRA-335140 trial (NCT06058013) in Major Depressive Disorder
2026-05-15
in 87 days 		ITCI Intra-Cellular Therapies, Inc. Lumateperone Trial Phase 3 โ€” $15B Primary completion for Lumateperone trial (NCT06462612) in Bipolar Disorder, Manic
2026-05-15
in 87 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Eribulin Trial Phase 3 โ€” $18B Primary completion for Eribulin trial (NCT06343948) in HR+HER2- Breast Cancer
2026-05-15
in 87 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Pemetrexed+Cisplatin or Carboplatin Trial Phase 3 โ€” $15B Primary completion for Pemetrexed+Cisplatin or Carboplatin trial (NCT06382116) in Non-smal
2026-05-15
in 87 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR T-DM1 Trial Phase 3 โ€” $15B Primary completion for T-DM1 trial (NCT06316531) in HER2-positive Breast Cancer
2026-05-15
in 87 days 		ARWR Arrowhead Pharmaceuticals, Inc. ARO-INHBE Trial Phase 2 โ€” $25B Primary completion for ARO-INHBE trial (NCT06700538) in Obesity
2026-05-15
in 87 days 		LLY Eli Lilly and Company Mevidalen Trial Phase 2 โ€” $15B Primary completion for Mevidalen trial (NCT06538116) in Alzheimer Disease
2026-05-15
in 87 days 		GLUE Monte Rosa Therapeutics, Inc. Oral MRT-2359 Trial Phase 2 โ€” $18B Primary completion for Oral MRT-2359 trial (NCT05546268) in NSCLC
2026-05-18
in 90 days 		REGN Regeneron Pharmaceuticals, Inc. Trevogrumab-Part A Trial Phase 2 โ€” $25B Primary completion for Trevogrumab-Part A trial (NCT06299098) in Obesity
2026-05-25
in 97 days 		AZNCF ASTRAZENECA PLC AZD9550 Trial Phase 2 โ€” $50B Primary completion for AZD6234 trial (NCT06862791) in Obesity or Overweight
2026-05-25
in 97 days 		AZN AstraZeneca PLC AZD9550 Trial Phase 2 โ€” $25B Primary completion for AZD9550 trial (NCT06862791) in Obesity or Overweight
2026-05-29
in 101 days 		NVS Novartis AG Ribociclib Trial Phase 3 โ€” $11B Primary completion for Ribociclib trial (NCT03701334) in Early Breast Cancer
2026-05-29
in 101 days 		AZNCF ASTRAZENECA PLC Benralizumab Trial Phase 3 โ€” $20B Primary completion for Benralizumab trial (NCT06465485) in Severe Eosinophilic Asthma
2026-05-29
in 101 days 		AZN AstraZeneca PLC Durvalumab Trial Phase 3 โ€” $15B Primary completion for Durvalumab trial (NCT03682068) in Unresectable Locally Advanced Uro
2026-05-29
in 101 days 		VRTX Vertex Pharmaceuticals Incorporated VX-264 Trial Phase 2 โ€” $15B Primary completion for VX-264 trial (NCT05791201) in Type 1 Diabetes
2026-05-30
in 102 days 		RHHBY Roche Holding AG Alectinib Trial Phase 3 โ€” $15B Primary completion for Alectinib trial (NCT03194893) in Neoplasms
2026-05-31
in 103 days 		TEVA Teva Pharmaceutical Industries Limited Fp/ABS Trial Phase 3 โ€” $20B Primary completion for Fp/ABS trial (NCT06664619) in Asthma
2026-05-31
in 103 days 		RHHBY Roche Holding AG Rituximab Trial Phase 3 โ€” $25B Primary completion for Rituximab trial (NCT04712097) in Relapsed or Refractory Follicular
2026-05-31
in 103 days 		STA Starton Holdings, Inc. Lenalidomide Trial Phase 2 โ€” $15B Primary completion for Lenalidomide trial (NCT06087653) in Multiple Myeloma
2026-05-31
in 103 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT04626479) in Carcinoma, Renal Cell
2026-05-31
in 103 days 		MRK MERCK MK-4830 Trial Phase 2 โ€” $15B Primary completion for MK-4830 trial (NCT04626518) in Carcinoma, Renal Cell
2026-05-31
in 103 days 		MRK MERCK Lenvatinib Trial Phase 3 โ€” $15B Primary completion for Lenvatinib trial (NCT04626479) in Carcinoma, Renal Cell
2026-06-01
in 173 days 		HNSPF Hansoh Pharmaceutical Group Co Limited/ADR HS-20117 Trial Phase 3 โ€” $10B Primary completion for HS-20117 trial (NCT06417008) in Non-Squamous Non-Small Cell Lung Ca
2026-06-01
in 173 days 		OTSKF OTSUKA Centanafadine Trial Phase 3 โ€” $15B Primary completion for Centanafadine trial (NCT06973577) in ADHD
2026-06-01
in 173 days 		MRTX Mirati Therapeutics, Inc. Adagrasib oral dose of 400 mg twice daily tablets Trial Phase 2 โ€” $15B Primary completion for Adagrasib oral dose of 400 mg twice daily tablets trial (NCT0560957
2026-06-02
in 174 days 		NVO Novo Nordisk A/S Tirzepatide Trial Phase 3 โ€” $35B Primary completion for Tirzepatide trial (NCT06534411) in Diabetes Mellitus, Type 2
2026-06-02
in 174 days 		AZN AstraZeneca PLC Durvalumab Trial Phase 3 โ€” $15B Primary completion for Durvalumab trial (NCT04550260) in Esophageal Squamous Cell Carcinom
2026-06-05
in 177 days 		ARVN Arvinas / Pfizer ยท NDA ESR1-mutated ER+/HER2- advanced or metastatic breast cancer (2L+) vepdegestrant (ARV-471 PDUFA โ€” 85% $10B JUN 5 2026 38 days ๐Ÿ’Š PDUFA (vepdegestrant (ARV-471)) $ARVN Arvinas / Pfizer ยท NDA ESR1-mut
2026-06-09
in 181 days 		NVO Novo Nordisk A/S Ziltivekimab B Trial Phase 3 โ€” $45B Primary completion for Ziltivekimab B trial (NCT05021835) in Cardiovascular Risk
2026-06-15
in 187 days 		AKBA Akebia Therapeutics, Inc. Vadadustat Trial Phase 3 โ€” $12B Primary completion for Vadadustat trial (NCT06901505) in Anemia of Chronic Kidney Disease
2026-06-15
in 187 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Eribulin Trial Phase 3 โ€” $18B Primary completion for Eribulin trial (NCT06382142) in Triple-Negative Breast Cancer
2026-06-15
in 187 days 		ARWR Arrowhead Pharmaceuticals, Inc. ARO-DIMERPA Trial Phase 2 โ€” $18B Primary completion for ARO-DIMERPA trial (NCT07223658) in Hyperlipidemia; Mixed
2026-06-15
in 187 days 		BIVI BIOVIE INC. NE3107 Trial Phase 3 โ€” $12B Primary completion for NE3107 trial (NCT06847191) in Long COVID
2026-06-15
in 187 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR HRS-5041 tablets Trial Phase 2 โ€” $15B Primary completion for HRS-5041 tablets trial (NCT06568094) in Prostate Cancer
2026-06-15
in 187 days 		ALKS Alkermes plc ALKS 5461 Trial Phase 3 โ€” $15B Primary completion for Placebo trial (NCT06843590) in Idiopathic Hypersomnia
2026-06-15
in 187 days 		LLY Eli Lilly and Company Tirzepatide Trial Phase 3 โ€” $15B Primary completion for Tirzepatide trial (NCT06143956) in Obesity
2026-06-15
in 187 days 		INCY Incyte Corporation ICS-LABA Trial Phase 2 โ€” $12B Primary completion for ICS-LABA trial (NCT05851443) in Moderate to Severe Asthma
2026-06-15
in 187 days 		CADL Candel Therapeutics, Inc. Aglatimagene besadenovec + valacyclovir Trial Phase 3 โ€” $15B Primary completion for aglatimagene besadenovec + valacyclovir trial (NCT07332000) in Pros
2026-06-15
in 187 days 		LLY Eli Lilly and Company LY3841136 Trial Phase 2 โ€” $25B Primary completion for LY3841136 trial (NCT06603571) in Obesity
2026-06-15
in 187 days 		CODX Co-Diagnostics, Inc. BL-M07D1 Trial Phase 2 โ€” $15B Primary completion for BL-M07D1 trial (NCT06445400) in HER2-positive Breast Cancer
2026-06-15
in 187 days 		LLY Eli Lilly and Company LY3305677 Trial Phase 2 โ€” $25B Primary completion for LY3305677 trial (NCT06143956) in Obesity
2026-06-15
in 187 days 		VSTM Verastem, Inc. avutometinib and sotorasib Trial Phase 2 โ€” $15B Primary completion for avutometinib and sotorasib trial (NCT05074810) in Non Small Cell Lu
2026-06-15
in 187 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR HRS-1167 tablets Trial Phase 2 โ€” $15B Primary completion for HRS-1167 tablets trial (NCT06568094) in Prostate Cancer
2026-06-16
in 188 days 		BNTX BioNTech SE Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose Trial Phase 3 โ€” $15B Primary completion for Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose tri
2026-06-17
in 189 days 		AZN AstraZeneca PLC AZD8421 Trial Phase 2 โ€” $12B Primary completion for AZD8421 trial (NCT06188520) in ER+ HER2- Advanced Breast Cancer
2026-06-19
in 191 days 		AZN AstraZeneca PLC Tozorakimab Trial Phase 3 โ€” $15B Primary completion for Tozorakimab trial (NCT05624450) in Viral Lung Infection and Acute R
2026-06-30
in 202 days 		AZN AstraZeneca ยท NDA HR+/HER2- advanced breast cancer โ€” 1L with emergent ESR1 mutation (with CDK4/6 inh camizestrant (AZD9833 PDUFA โ€” 85% $12B JUN 30 2026 63 days ๐Ÿ’Š PDUFA (camizestrant (AZD9833)) $AZN AstraZeneca ยท NDA HR+/HER2- adva
2026-06-30
in 202 days 		WVE Wave Life Sciences Ltd. โ€” Trial 1 โ€” $25B Three-month follow-up data from 600 mg Cohort 4 Phase 1 trial of WVE-007 (INLIGHT)
2026-06-30
in 202 days 		RAPP Candel Therapeutics, Inc. โ€” Trial 3 โ€” $15B Follow-up clinical data from phase 3 trial of Aglatimagene besadenovec (CAN-2409)
2026-06-30
in 202 days 		PFE PFIZER Carboplatin Trial Phase 3 โ€” $15B Primary completion for carboplatin trial (NCT05911295) in Urothelial Carcinoma
2026-06-30
in 202 days 		RHHBY Roche Holding AG Pemetrexed Trial Phase 3 โ€” $15B Primary completion for Pemetrexed trial (NCT05112965) in Neoplasms
2026-06-30
in 202 days 		AZN AstraZeneca PLC Durvalumab Trial Phase 3 โ€” $15B Primary completion for Durvalumab trial (NCT05221840) in Non-Small Cell Lung Cancer
2026-06-30
in 202 days 		RHHBY Roche Holding AG Inavolisib Trial Phase 3 โ€” $18B Primary completion for Inavolisib trial (NCT05646862) in Breast Cancer
2026-06-30
in 202 days 		PFE PFIZER cisplatin Trial Phase 3 โ€” $15B Primary completion for cisplatin trial (NCT05911295) in Urothelial Carcinoma
2026-06-30
in 202 days 		SBFM Sunshine Biopharma Inc. 611 300 mg Q2W Trial Phase 2 โ€” $15B Primary completion for Matching placebo trial (NCT07042126) in Dermatitis, Atopic
2026-06-30
in 202 days 		CELC Celcuity Inc. (CELC) Palbociclib Trial Phase 3 โ€” $18B Primary completion for Palbociclib trial (NCT05501886) in Breast Cancer
2026-06-30
in 202 days 		SBFM Sunshine Biopharma Inc. 611 Trial Phase 3 โ€” $15B Primary completion for 611 trial (NCT07042126) in Dermatitis, Atopic
2026-06-30
in 202 days 		OLMA Olema Pharmaceuticals, Inc. Palazestrant Trial Phase 3 โ€” $18B Primary completion for Palazestrant trial (NCT06016738) in Breast Cancer
2026-06-30
in 202 days 		AZNCF ASTRAZENECA PLC Oleclumab Trial Phase 2 โ€” $15B Primary completion for Oleclumab trial (NCT06606847) in Non-Small Cell Lung Cancer
2026-06-30
in 202 days 		MAIA MAIA Biotechnology, Inc. 6-Thio-2'-Deoxyguanosine Trial Phase 3 โ€” $15B Primary completion for 6-Thio-2'-Deoxyguanosine trial (NCT05208944) in Carcinoma, Non-Smal
2026-06-30
in 202 days 		MRTX Mirati Therapeutics, Inc. MRTX849 Trial Phase 3 โ€” $13B Primary completion for MRTX849 trial (NCT05578092) in Solid Tumor
2026-07-01
in 273 days 		ALMS ALUMIS INC. ESK-001 Trial Phase 3 โ€” $12B Primary completion for ESK-001 trial (NCT05966480) in SLE
2026-07-01
in 273 days 		ANRO Alto Neuroscience, Inc. LM-302 Trial Phase 3 โ€” $22B Primary completion for LM-302 trial (NCT05934331) in Malignant Neoplasms of Digestive Orga
2026-07-06
in 278 days 		MRK MERCK Paclitaxel Trial Phase 3 โ€” $12B Primary completion for Paclitaxel trial (NCT04380636) in Lung Neoplasms
2026-07-06
in 278 days 		MRK MERCK Raludotatug Deruxtecan (R-DXd) Trial Phase 2 โ€” $15B Primary completion for Raludotatug Deruxtecan (R-DXd) trial (NCT06864169) in Gastrointesti
2026-07-07
in 279 days 		AZN AstraZeneca PLC Osimertinib Trial Phase 3 โ€” $12B Primary completion for Osimertinib trial (NCT06194448) in Lung Cancer
2026-07-15
in 287 days 		LXRX LEXICON PHARMACEUTICALS, INC. Sotagliflozin Trial Phase 3 โ€” $55B Primary completion for Sotagliflozin trial (NCT06481891) in Obstructive Cardiomyopathy, Hy
2026-07-15
in 287 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SKB264 Trial Phase 3 โ€” $15B Primary completion for SKB264 trial (NCT06279364) in Triple Negative Breast Cancer
2026-07-15
in 287 days 		ONC BeOne Medicines Ltd. Tislelizumab Trial Phase 3 โ€” $19B Primary completion for Tislelizumab trial (NCT04164199) in Advanced Malignancies
2026-07-15
in 287 days 		GSK GSK plc GSK5784283 Trial Phase 2 โ€” $20B Primary completion for GSK5784283 trial (NCT06748053) in Asthma
2026-07-15
in 287 days 		GSK GSK plc Paclitaxel Trial Phase 3 โ€” $31B Primary completion for Paclitaxel trial (NCT06317311) in Carcinoma
2026-07-15
in 287 days 		ABBV AbbVie Inc. Telisotuzumab vedotin Trial Phase 3 โ€” $15B Primary completion for Telisotuzumab vedotin trial (NCT03539536) in Non-small Cell Lung Ca
2026-07-15
in 287 days 		ARWR Arrowhead Pharmaceuticals, Inc. ARO-ALK7 Trial Phase 2 โ€” $25B Primary completion for ARO-ALK7 trial (NCT06937203) in Obesity
2026-07-15
in 287 days 		BIO BIO-RAD LABORATORIES, INC. VRB-101 Trial Phase 2 โ€” $25B Primary completion for VRB-101 trial (NCT07281937) in Obesity
2026-07-15
in 287 days 		CODX Co-Diagnostics, Inc. PD-1 Monoclonal Antibody Trial Phase 2 โ€” $15B Primary completion for PD-1 Monoclonal Antibody trial (NCT06475300) in Non-small Cell Lung
2026-07-15
in 287 days 		GPCR Structure Therapeutics Inc. Aleniglipron Trial Phase 2 โ€” $50B Primary completion for Aleniglipron trial (NCT06693843) in Obesity, Overweight, or Chronic
2026-07-17
in 289 days 		TEVA Teva Pharmaceutical Industries Limited TEV-56248 Trial Phase 3 โ€” $20B Primary completion for TEV-56248 trial (NCT06052267) in Asthma
2026-07-23
in 295 days 		BNTX BioNTech SE Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose Trial Phase 3 โ€” $15B Primary completion for Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose tri
2026-07-23
in 295 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT04123366) in Solid Tumors
2026-07-24
in 296 days 		AZN AstraZeneca PLC exenatide Trial Phase 3 โ€” $55B Primary completion for Placebo trial (NCT06151964) in Overweight and Obesity
2026-07-24
in 296 days 		AZN AstraZeneca PLC AZD9550 Trial Phase 2 โ€” $25B Primary completion for AZD9550 trial (NCT06151964) in Overweight and Obesity
2026-07-25
in 297 days 		BIIB Eisai / Biogen ยท sNDA Subcutaneous formulation โ€” early Alzheimer's disease Leqembi (lecanemab PDUFA โ€” 92% $15B JUL 25 2026 88 days ๐Ÿ’Š PDUFA Leqembi (lecanemab) $BIIB Eisai / Biogen ยท sNDA Subcutaneous f
2026-07-26
in 298 days 		NVAX Novavax, Inc. CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant Trial Phase 3 โ€” $15B Primary completion for CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvan
2026-07-27
in 299 days 		AZN AstraZeneca PLC Olaparib Trial Phase 3 โ€” $12B Primary completion for Olaparib trial (NCT04884360) in Ovarian Cancer
2026-07-30
in 302 days 		PFE PFIZER ritonavir Trial Phase 3 โ€” $15B Primary completion for ritonavir trial (NCT05261139) in COVID-19
2026-07-30
in 302 days 		PFE PFIZER Nirmatrelvir Trial Phase 3 โ€” $15B Primary completion for nirmatrelvir trial (NCT05261139) in COVID-19
2026-07-30
in 302 days 		SBFM Sunshine Biopharma Inc. Pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT06980272) in Advanced Non-Small Cell Lung C
2026-07-30
in 302 days 		MRTX Mirati Therapeutics, Inc. Adagrasib Trial Phase 3 โ€” $15B Primary completion for Adagrasib trial (NCT05853575) in Advanced Cancer
2026-07-31
in 303 days 		BNTX BioNTech SE BNT162b2 Vaccine Trial Phase 3 โ€” $15B Primary completion for BNT162b2 Vaccine trial (NCT07300839) in COVID-19
2026-07-31
in 303 days 		BNTX BioNTech SE BNT162b2 (2025/2026 formulation) Trial Phase 3 โ€” $15B Primary completion for BNT162b2 (2025/2026 formulation) trial (NCT07222384) in COVID-19
2026-07-31
in 303 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT06698042) in Lung Cancer
2026-07-31
in 303 days 		WXI WUXI Semaglutide Trial Phase 3 โ€” $55B Primary completion for Semaglutide trial (NCT07064486) in Type 2 Diabetes (T2DM)
2026-07-31
in 303 days 		WXI WUXI BGM0504 Trial Phase 3 โ€” $25B Primary completion for BGM0504 trial (NCT07064486) in Type 2 Diabetes (T2DM)
2026-07-31
in 303 days 		JAZZ Jazz Pharmaceuticals plc Zanidatamab Trial Phase 3 โ€” $15B Primary completion for Zanidatamab trial (NCT05152147) in Gastric Neoplasms
2026-07-31
in 303 days 		BIOE Bio Essence Corp JMT202 injection Trial Phase 2 โ€” $12B Primary completion for JMT202 injection trial (NCT07140809) in Hypertriglyceridemia
2026-07-31
in 303 days 		AZN AstraZeneca PLC Dapagliflozin Trial Phase 3 โ€” $15B Primary completion for Dapagliflozin trial (NCT06942910) in Chronic Kidney Disease With Hi
2026-08-01
in 373 days 		RHHBY Roche Holding AG Zifibancimig Trial Phase 2 โ€” $10B Primary completion for Zifibancimig trial (NCT04567303) in Macular Degeneration
2026-08-03
in 375 days 		DSKYF Daiichi Sankyo T-DXd Trial Phase 3 โ€” $16B Primary completion for T-DXd trial (NCT06174987) in Advanced Cancer
2026-08-05
in 377 days 		SNYNF Sanofi Amlitelimab Trial Phase 3 โ€” $20B Primary completion for Amlitelimab trial (NCT06557772) in Coeliac Disease
2026-08-05
in 377 days 		MRNA Moderna, Inc. Influenza Vaccine PDUFA Phase 3 โ€” $15B For influenza. The FDA reversed its earlier Refusal-to-File decision and agreed to review
2026-08-05
in 377 days 		VRNA VERONA PHARMA Glycopyrrolate 21.25 mcg Trial Phase 2 โ€” $15B Primary completion for Ensifentrine 3 mg trial (NCT07016412) in Chronic Obstructive Pulmon
2026-08-06
in 378 days 		AZN AstraZeneca PLC AZD6234 Trial Phase 2 โ€” $50B Primary completion for AZD6234 trial (NCT07017179) in Obesity/Overweight
2026-08-07
in 379 days 		SNY Sanofi Itepekimab (SAR440340) Trial Phase 3 โ€” $15B Primary completion for Itepekimab (SAR440340) trial (NCT06691113) in Chronic Rhinosinusiti
2026-08-13
in 385 days 		ZEAL Zealand Pharma A/S Petrelintide Trial Phase 2 โ€” $25B Primary completion for Petrelintide trial (NCT06926842) in Overweight
2026-08-15
in 387 days 		HELP CYBIN INC. CYB003 Trial Phase 3 โ€” $15B Primary completion for CYB003 trial (NCT06564818) in Major Depressive Disorder
2026-08-15
in 387 days 		LLY Eli Lilly and Company Retatrutide Trial Phase 3 โ€” $25B Primary completion for Retatrutide trial (NCT06260722) in Diabetes Mellitus, Type 2
2026-08-15
in 387 days 		LLY Eli Lilly and Company Semaglutide Trial Phase 3 โ€” $55B Primary completion for Semaglutide trial (NCT06260722) in Diabetes Mellitus, Type 2
2026-08-15
in 387 days 		ABBV AbbVie Inc. Pomalidomide Trial Phase 3 โ€” $15B Primary completion for Pomalidomide trial (NCT03539744) in Multiple Myeloma
2026-08-15
in 387 days 		XENE Xenon Pharmaceuticals Inc. Azetukalner Trial Phase 3 โ€” $15B Primary completion for Azetukalner trial (NCT06775379) in Major Depressive Disorder
2026-08-15
in 387 days 		MPLT MapLight Therapeutics, Inc. ML-007C-MA BID Trial Phase 2 โ€” $12B Primary completion for ML-007C-MA BID trial (NCT07038876) in Schizophrenia
2026-08-15
in 387 days 		GILD Gilead Sciences, Inc. Domvanalimab Trial Phase 3 โ€” $15B Primary completion for Domvanalimab trial (NCT06727565) in Head and Neck Squamous Cell Car
2026-08-15
in 387 days 		CPHI CHINA PHARMA HOLDINGS, INC. ASC30 tablets Trial Phase 2 โ€” $45B Primary completion for ASC30 tablets trial (NCT07321678) in T2DM (Type 2 Diabetes Mellitus
2026-08-15
in 387 days 		ANRO Alto Neuroscience, Inc. ALTO-203 25 ฮผg Trial Phase 2 โ€” $15B Primary completion for Placebo trial (NCT06656416) in Bipolar Disorder I or II With a Majo
2026-08-15
in 387 days 		ANRO Alto Neuroscience, Inc. ALTO-100 Trial Phase 2 โ€” $10B Primary completion for ALTO-100 trial (NCT06656416) in Bipolar Disorder I or II With a Maj
2026-08-15
in 387 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Osimertinib Mesylate Tablets Trial Phase 2 โ€” $15B Primary completion for Osimertinib Mesylate Tablets trial (NCT06498986) in Non-small Cell
2026-08-15
in 387 days 		IGC IGC Pharma, Inc. IGC-AD1-Active Trial Phase 2 โ€” $15B Primary completion for IGC-AD1-Active trial (NCT05543681) in Alzheimer Disease
2026-08-17
in 389 days 		PFE PFIZER BAT Trial Phase 2 โ€” $12B Primary completion for BAT trial (NCT05639647) in Gram-negative Bacterial Infections
2026-08-18
in 390 days 		MRK MERCK Raludotatug Deruxtecan (R-DXd) Trial Phase 2 โ€” $15B Primary completion for Raludotatug Deruxtecan (R-DXd) trial (NCT06864169) in Gastrointesti
2026-08-19
in 391 days 		MRK MERCK etoposide Trial Phase 3 โ€” $15B Primary completion for etoposide trial (NCT05298423) in Carcinoma, Non-Small-Cell Lung
2026-08-19
in 391 days 		MRK MERCK Pembrolizumab/Vibostolimab Trial Phase 3 โ€” $12B Primary completion for pembrolizumab/vibostolimab trial (NCT05298423) in Carcinoma, Non-Sm
2026-08-19
in 391 days 		AZN AstraZeneca PLC Volrustomig Trial Phase 3 โ€” $15B Primary completion for Volrustomig trial (NCT05489211) in Endometrial Cancer
2026-08-19
in 391 days 		AZN AstraZeneca PLC Capecitabine Trial Phase 3 โ€” $12B Primary completion for Capecitabine trial (NCT05489211) in Endometrial Cancer
2026-08-19
in 391 days 		AZN AstraZeneca PLC Datopotamab deruxtecan (Dato-DXd) Trial Phase 3 โ€” $15B Primary completion for Datopotamab deruxtecan (Dato-DXd) trial (NCT05489211) in Endometria
2026-08-21
in 393 days 		NVO Novo Nordisk A/S Oral semaglutide Trial Phase 3 โ€” $35B Primary completion for Oral semaglutide trial (NCT07271251) in Type 2 Diabetes
2026-08-21
in 393 days 		NVO Novo Nordisk A/S CagriSema (Cagrilintide B and Semaglutide I) Trial Phase 3 โ€” $25B Primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT06797869) in
2026-08-23
in 395 days 		PFE PFIZER PF-07220060 + PF-07104091 combination dose escalation Trial Phase 2 โ€” $18B Primary completion for PF-07220060 + PF-07104091 combination dose escalation trial (NCT052
2026-08-24
in 396 days 		AZN AstraZeneca PLC AZD9833 Trial Phase 3 โ€” $15B Primary completion for AZD9833 trial (NCT04711252) in ER-Positive HER2-Negative Breast Can
2026-08-24
in 396 days 		UCBJY UCB Brivaracetam Trial Phase 3 โ€” $15B Primary completion for Brivaracetam trial (NCT04666610) in Childhood Absence Epilepsy
2026-08-24
in 396 days 		RHHBY Roche Holding AG RO7204239 Trial Phase 3 โ€” $25B Primary completion for RO7204239 trial (NCT06965413) in Obesity
2026-08-25
in 397 days 		RHHBY Roche Holding AG Iberdomide PDUFA Phase 2 โ€” $15B NDA filing. AI-extracted from news: FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdom
2026-08-27
in 399 days 		CLTS EARTH LIFE SCIENCES INC Lutetium (177Lu) rhPSMA-10.1 Injection Trial Phase 2 โ€” $15B Primary completion for Lutetium (177Lu) rhPSMA-10.1 Injection trial (NCT05413850) in Prost
2026-08-28
in 400 days 		AZN AstraZeneca PLC AZD2936 Trial Phase 2 โ€” $15B Primary completion for AZD2936 trial (NCT04995523) in Non-Small-Cell Lung Carcinoma
2026-08-28
in 400 days 		RHHBY Roche Holding AG Carboplatin Trial Phase 3 โ€” $18B Primary completion for Carboplatin trial (NCT06624059) in Non-Small Cell Lung Cancer
2026-08-28
in 400 days 		RHHBY Roche Holding AG Pemetrexed Trial Phase 3 โ€” $15B Primary completion for Pemetrexed trial (NCT06624059) in Non-Small Cell Lung Cancer
2026-08-28
in 400 days 		RHHBY Roche Holding AG Alectinib Trial Phase 3 โ€” $15B Primary completion for Alectinib trial (NCT06624059) in Non-Small Cell Lung Cancer
2026-08-30
in 402 days 		PFE PFIZER Elranatamab Trial Phase 3 โ€” $15B Primary completion for Elranatamab trial (NCT06152575) in Multiple Myeloma
2026-08-30
in 402 days 		PFE PFIZER Elotuzumab Trial Phase 3 โ€” $15B Primary completion for Elotuzumab trial (NCT06152575) in Multiple Myeloma
2026-08-31
in 403 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Wujia Yizhi granules Trial Phase 3 โ€” $15B Primary completion for Wujia Yizhi granules trial (NCT06534723) in Alzheimer's Dementia
2026-09-01
in 473 days 		NVO Novo Nordisk A/S NNC0519-0130 Trial Phase 2 โ€” $35B Primary completion for NNC0519-0130 trial (NCT06717698) in Chronic Kidney Disease
2026-09-01
in 473 days 		NVO Novo Nordisk A/S Semaglutide Trial Phase 3 โ€” $25B Primary completion for Semaglutide trial (NCT06717698) in Chronic Kidney Disease
2026-09-01
in 473 days 		PFE PFIZER Abemaciclib Trial Phase 3 โ€” $18B Primary completion for ARV-471 trial (NCT05548127) in Breast Cancer
2026-09-03
in 475 days 		NVO Novo Nordisk A/S Ziltivekimab Trial Phase 3 โ€” $25B Primary completion for Ziltivekimab trial (NCT06118281) in Cardiovascular Risk
2026-09-15
in 487 days 		ITCI Intra-Cellular Therapies, Inc. Lumateperone Trial Phase 3 โ€” $15B Primary completion for Lumateperone trial (NCT05850689) in Major Depressive Disorder
2026-09-15
in 487 days 		MRK MERCK Paclitaxel Trial Phase 3 โ€” $12B Primary completion for Paclitaxel trial (NCT04634877) in Endometrial Neoplasms
2026-09-15
in 487 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT04634877) in Endometrial Neoplasms
2026-09-15
in 487 days 		ALKS Alkermes plc OLZ/SAM Trial Phase 3 โ€” $12B Primary completion for OLZ/SAM trial (NCT05303064) in Schizophrenia
2026-09-15
in 487 days 		NVS Novartis AG Alpelisib Trial Phase 3 โ€” $12B Primary completion for Alpelisib trial (NCT05038735) in Breast Cancer
2026-09-15
in 487 days 		NVS Novartis AG Fulvestrant Trial Phase 3 โ€” $18B Primary completion for Fulvestrant trial (NCT05038735) in Breast Cancer
2026-09-15
in 487 days 		ALKS Alkermes plc ALKS 3831 Trial Phase 3 โ€” $12B Primary completion for Olanzapine trial (NCT05303064) in Schizophrenia
2026-09-15
in 487 days 		LLY Eli Lilly and Company Tirzepatide Trial Phase 3 โ€” $15B Primary completion for Tirzepatide trial (NCT05536804) in Overweight
2026-09-15
in 487 days 		MOLN MOLECULAR PARTNERS AG PMD-026 Trial Phase 2 โ€” $15B Primary completion for PMD-026 trial (NCT04115306) in Metastatic Breast Cancer
2026-09-15
in 487 days 		ORKA Oruka Therapeutics, Inc. ORKA-001 Induction Dose Trial Phase 2 โ€” $12B Primary completion for ORKA-001 Induction Dose trial (NCT07090330) in Plaque Psoriasis
2026-09-15
in 487 days 		SBFM Sunshine Biopharma Inc. 610 Trial Phase 3 โ€” $20B Primary completion for 610 trial (NCT06680947) in Asthma
2026-09-15
in 487 days 		PCSA Processa Pharmaceuticals, Inc. PCS6422 and capecitabine Trial Phase 2 โ€” $18B Primary completion for PCS6422 and capecitabine trial (NCT06568692) in Breast Cancer
2026-09-15
in 487 days 		GILD Gilead Sciences, Inc. Pembrolizumab Trial Phase 2 โ€” $15B Primary completion for Sacituzumab Govitecan-hziy (SG) trial (NCT05186974) in Non-small Ce
2026-09-15
in 487 days 		BHVN Biohaven Pharmaceutical Holding Company Ltd. Taldefgrobep Alfa Trial Phase 3 โ€” $25B Primary completion for Taldefgrobep Alfa trial (NCT07281495) in Obesity
2026-09-15
in 487 days 		CYTK Cytokinetics, Incorporated CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) Trial Phase 2 โ€” $15B Primary completion for CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) trial (NCT06793371)
2026-09-17
in 489 days 		VRTX Vertex Pharmaceuticals Incorporated Biological/Vaccine Trial Phase 3 โ€” $15B Primary completion for Biological/Vaccine trial (NCT06832410) in Type 1 Diabetes
2026-09-21
in 493 days 		PFE PFIZER PF-07275315 Trial Phase 2 โ€” $20B Primary completion for PF-07275315 trial (NCT05995964) in Atopic Dermatitis
2026-09-28
in 500 days 		RHHBY Roche Holding AG Inavolisib Trial Phase 3 โ€” $18B Primary completion for Inavolisib trial (NCT05894239) in Metastatic Breast Cancer
2026-09-28
in 500 days 		RHHBY Roche Holding AG Phesgo Trial Phase 3 โ€” $15B Primary completion for Phesgo trial (NCT05894239) in Metastatic Breast Cancer
2026-09-28
in 500 days 		RHHBY Roche Holding AG Optional Endocrine Therapy of Investigator's Choice Trial Phase 3 โ€” $15B Primary completion for Optional Endocrine Therapy of Investigator's Choice trial (NCT05894
2026-09-28
in 500 days 		RHHBY Roche Holding AG Taxane-based chemotherapy Trial Phase 3 โ€” $18B Primary completion for Taxane-based Chemotherapy trial (NCT05894239) in Metastatic Breast
2026-09-30
in 502 days 		AZN AstraZeneca PLC Pemetrexed Trial Phase 3 โ€” $15B Primary completion for Pemetrexed trial (NCT06417814) in Metastatic Non-small Cell Lung Ca
2026-09-30
in 502 days 		RYTM RHYTHM PHARMACEUTICALS, INC. Setmelanotide Trial Phase 3 โ€” $15B Primary completion for Setmelanotide trial (NCT06760546) in Hypothalamic Obesity
2026-09-30
in 502 days 		AZN AstraZeneca PLC Dato-DXd Trial Phase 3 โ€” $18B Primary completion for Dato-DXd trial (NCT06417814) in Metastatic Non-small Cell Lung Canc
2026-09-30
in 502 days 		AZN AstraZeneca PLC Osimertinib Trial Phase 3 โ€” $12B Primary completion for Osimertinib trial (NCT06417814) in Metastatic Non-small Cell Lung C
2026-09-30
in 502 days 		GSK GSK plc GSK4527226 Trial Phase 2 โ€” $15B Primary completion for GSK4527226 trial (NCT06079190) in Alzheimer's Disease
2026-09-30
in 502 days 		TAK TAKEDA PHARMACEUTICAL CO LTD TAK-279 Trial Phase 3 โ€” $12B Primary completion for TAK-279 trial (NCT06254950) in Ulcerative Colitis
2026-09-30
in 502 days 		AZN AstraZeneca PLC Rosuvastatin Trial Phase 3 โ€” $28B Primary completion for Rosuvastatin trial (NCT07218900) in Dyslipidaemia
2026-09-30
in 502 days 		DSKYF Daiichi Sankyo CS-1008 Trial Phase 2 โ€” $15B Primary completion for Carboplatin trial (NCT06362252) in Extensive Stage-small Cell Lung
2026-09-30
in 502 days 		RHHBY Roche Holding AG Prednisone Trial Phase 3 โ€” $15B Primary completion for Prednisone trial (NCT04980222) in Lymphoma
2026-09-30
in 502 days 		RHHBY Roche Holding AG tocilizumab Trial Phase 3 โ€” $25B Primary completion for Tocilizumab trial (NCT03533283) in Non-Hodgkins Lymphoma
2026-10-01
in 573 days 		NVO Novo Nordisk A/S Ziltivekimab Trial Phase 3 โ€” $25B Primary completion for Ziltivekimab trial (NCT06200207) in Heart Failure
2026-10-05
in 577 days 		NVO Novo Nordisk A/S Ziltivekimab Trial Phase 3 โ€” $25B Primary completion for Ziltivekimab trial (NCT06200207) in Heart Failure
2026-10-06
in 578 days 		AZN AstraZeneca PLC Benralizumab Trial Phase 3 โ€” $20B Primary completion for Benralizumab trial (NCT06512883) in Eosinophilic Granulomatosis Wit
2026-10-13
in 585 days 		BIOE Bio Essence Corp JSKN003 Trial Phase 3 โ€” $12B Primary completion for JSKN003 trial (NCT06846437) in Unrespectable Locally Advanced and o
2026-10-15
in 587 days 		LLY Eli Lilly and Company LY3537982 Trial Phase 3 โ€” $15B Primary completion for LY3537982 trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung
2026-10-15
in 587 days 		ABBV AbbVie Inc. Aflibercept (EYLEAยฎ) Trial Phase 3 โ€” $15B Primary completion for Aflibercept (EYLEAยฎ) trial (NCT05407636) in AMD
2026-10-15
in 587 days 		LLY Eli Lilly and Company Retatrutide Trial Phase 3 โ€” $25B Primary completion for Retatrutide trial (NCT06297603) in Type 2 Diabetes
2026-10-15
in 587 days 		LLY Eli Lilly and Company carboplatin Trial Phase 3 โ€” $18B Primary completion for Carboplatin trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung
2026-10-15
in 587 days 		CODX Co-Diagnostics, Inc. Tapinarof cream, 1% Trial Phase 3 โ€” $12B Primary completion for tapinarof cream, 1% trial (NCT05172726) in Plaque Psoriasis
2026-10-15
in 587 days 		LLY Eli Lilly and Company pemetrexed Trial Phase 3 โ€” $15B Primary completion for Pemetrexed trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung
2026-10-15
in 587 days 		LLY Eli Lilly and Company cisplatin Trial Phase 3 โ€” $15B Primary completion for Cisplatin trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung
2026-10-15
in 587 days 		LLY Eli Lilly and Company Pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung
2026-10-15
in 587 days 		VNDA Vanda Pharmaceuticals Inc. iloperidone Trial Phase 3 โ€” $12B Primary completion for iloperidone trial (NCT07090161) in Hypertension
2026-10-15
in 587 days 		GPCR Structure Therapeutics Inc. Aleniglipron Trial Phase 2 โ€” $50B Primary completion for Aleniglipron trial (NCT07400588) in Obese
2026-10-15
in 587 days 		GILD Gilead Sciences, Inc. Optimized Background Regimen (OBR) Trial Phase 3 โ€” $28B Primary completion for Optimized Background Regimen (OBR) trial (NCT06749054) in HIV-1-inf
2026-10-15
in 587 days 		GILD Gilead Sciences, Inc. Oral Lenacapavir Trial Phase 3 โ€” $28B Primary completion for Oral Lenacapavir trial (NCT06749054) in HIV-1-infection
2026-10-15
in 587 days 		ABOS Acumen Pharmaceuticals, Inc. sabirnetug Trial Phase 2 โ€” $15B Primary completion for sabirnetug trial (NCT06335173) in Alzheimer Disease
2026-10-15
in 587 days 		IPIX Innovation Pharmaceuticals Inc. GI-101 Trial Phase 2 โ€” $15B Primary completion for GI-101 trial (NCT04977453) in Advanced Solid Tumor
2026-10-18
in 590 days 		BGNE BeiGene, Ltd. BGB-45035 Trial Phase 2 โ€” $25B Primary completion for BGB-45035 trial (NCT07100938) in Rheumatoid Arthritis
2026-10-19
in 591 days 		AMGN Amgen Inc. Rocatinlimab Trial Phase 3 โ€” $20B Primary completion for Rocatinlimab trial (NCT06376045) in Asthma
2026-10-20
in 592 days 		OTSKF OTSUKA SEP-363856 Trial Phase 3 โ€” $12B Primary completion for SEP-363856 trial (NCT06894212) in Schizophrenia
2026-10-23
in 595 days 		AZN AstraZeneca PLC Durvalumab Trial Phase 3 โ€” $15B Primary completion for Durvalumab trial (NCT06040099) in Hepatocellular Carcinoma (HCC)
2026-10-26
in 598 days 		NVS Novartis AG Inclisiran sodium 300 mg Trial Phase 3 โ€” $18B Primary completion for Inclisiran sodium 300 mg trial (NCT05360446) in Coronary Artery Dis
2026-10-27
in 599 days 		AZN AstraZeneca PLC Volrustomig Trial Phase 3 โ€” $15B Primary completion for Volrustomig trial (NCT05775159) in Hepatocellular Carcinoma
2026-10-29
in 601 days 		MRK MERCK Lenvatinib Trial Phase 3 โ€” $15B Primary completion for Lenvatinib trial (NCT04736706) in Carcinoma, Renal Cell
2026-10-29
in 601 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT04736706) in Carcinoma, Renal Cell
2026-10-29
in 601 days 		MRK MERCK tildrakizumab PDUFA Phase 2 โ€” $12B For Adults with Active Psoriatic Arthritis If the sBLA is approved. sbla filing. AI-extra
2026-10-30
in 602 days 		AMGN Amgen Inc. Rocatinlimab Trial Phase 3 โ€” $20B Primary completion for Rocatinlimab trial (NCT06527404) in Prurigo Nodularis
2026-10-30
in 602 days 		BNTX BioNTech SE BNT162b2 (2025/2026 formulation) Trial Phase 3 โ€” $15B Primary completion for BNT162b2 (2025/2026 formulation) trial (NCT07222384) in COVID-19
2026-10-30
in 602 days 		INBX Inhibrx Biosciences, Inc. INBRX-106 - Hexavalent OX40 agonist antibody Trial Phase 2 โ€” $13B Primary completion for INBRX-106 - Hexavalent OX40 agonist antibody trial (NCT04198766) in
2026-10-31
in 603 days 		RHHBY Roche Holding AG Carboplatin Trial Phase 3 โ€” $18B Primary completion for Carboplatin trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Docetaxel Trial Phase 3 โ€” $15B Primary completion for Docetaxel trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		AZN AstraZeneca PLC Fulvestrant Trial Phase 3 โ€” $18B Primary completion for Fulvestrant trial (NCT06635447) in Breast Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Entrectinib Trial Phase 3 โ€” $18B Primary completion for Entrectinib trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Alectinib Trial Phase 3 โ€” $15B Primary completion for Alectinib trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Pemetrexed Trial Phase 3 โ€” $15B Primary completion for Pemetrexed trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		RHHBY Roche Holding AG Divarasib Trial Phase 3 โ€” $15B Primary completion for Divarasib trial (NCT03178552) in Non-Small Cell Lung Cancer
2026-10-31
in 603 days 		IMMP Immutep Limited eftilagimod alpha Trial Phase 3 โ€” $18B Primary completion for eftilagimod alpha trial (NCT05747794) in Breast Carcinoma
2026-10-31
in 603 days 		TEVA Teva Pharmaceutical Industries Limited TEV-56248 Trial Phase 3 โ€” $20B Primary completion for TEV-56248 trial (NCT06052267) in Asthma
2026-10-31
in 603 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR SHR6390 Trial Phase 3 โ€” $12B Primary completion for SHR6390 trial (NCT04842617) in Hormone Receptor Positive,Human Epid
2026-10-31
in 603 days 		RYTM RHYTHM PHARMACEUTICALS, INC. Setmelanotide Trial Phase 3 โ€” $15B Primary completion for Setmelanotide trial (NCT06772597) in Prader-Willi Syndrome
2026-10-31
in 603 days 		TAK TAKEDA PHARMACEUTICAL CO LTD TAK-788 Trial Phase 2 โ€” $15B Primary completion for TAK-788 trial (NCT02716116) in Carcinoma, Non-Small-Cell Lung
2026-10-31
in 603 days 		SYRE Spyre Therapeutics, Inc. SPY002-072 Trial Phase 2 โ€” $25B Primary completion for SPY002-072 trial (NCT07148414) in Rheumatoid Arthritis
2026-10-31
in 603 days 		RHHBY Roche Holding AG Nab-paclitaxel Trial Phase 3 โ€” $15B Primary completion for Nab-Paclitaxel trial (NCT05852691) in Breast Cancer
2026-10-31
in 603 days 		ADAG Adagene Inc. ADG126 Trial Phase 2 โ€” $15B Primary completion for ADG126 trial (NCT05405595) in Advanced/Metastatic Solid Tumors
2026-11-01
in 673 days 		CRBP Corbus Pharmaceuticals Holdings, Inc. CRB-601 monoclonal antibody Trial Phase 2 โ€” $14B Primary completion for CRB-601 monoclonal antibody trial (NCT06603844) in Solid Tumor
2026-11-07
in 679 days 		MRK MERCK Lenvatinib Trial Phase 3 โ€” $15B Primary completion for Lenvatinib trial (NCT05319730) in Esophageal Squamous Cell Carcinom
2026-11-07
in 679 days 		MRK MERCK Paclitaxel Trial Phase 3 โ€” $12B Primary completion for Paclitaxel trial (NCT05319730) in Esophageal Squamous Cell Carcinom
2026-11-07
in 679 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT05319730) in Esophageal Squamous Cell Carci
2026-11-07
in 679 days 		MRK MERCK Supportive care measures Trial Phase 3 โ€” $15B Primary completion for Supportive care measures trial (NCT05319730) in Esophageal Squamous
2026-11-07
in 679 days 		MRK MERCK MK-4830 Trial Phase 2 โ€” $15B Primary completion for MK-4830 trial (NCT05319730) in Esophageal Squamous Cell Carcinoma
2026-11-09
in 681 days 		BIO BIO-RAD LABORATORIES, INC. BAT8010 for Injection Trial Phase 2 โ€” $14B Primary completion for BAT8010 for Injection trial (NCT06376136) in Advanced Solid Tumors
2026-11-12
in 684 days 		RHHBY Roche Holding AG Ocrelizumab Trial Phase 3 โ€” $28B Primary completion for Ocrelizumab trial (NCT03523858) in Progressive Multiple Sclerosis (
2026-11-15
in 687 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Capecitabine Trial Phase 3 โ€” $15B Primary completion for capecitabine trial (NCT06118333) in Nasopharyngeal Carcinoma
2026-11-15
in 687 days 		LLY Eli Lilly and Company Tirzepatide Trial Phase 3 โ€” $15B Primary completion for Tirzepatide trial (NCT06662383) in Obesity
2026-11-15
in 687 days 		LLY Eli Lilly and Company Orforglipron Trial Phase 3 โ€” $25B Primary completion for Orforglipron trial (NCT06649045) in OSA
2026-11-15
in 687 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SKB264 Trial Phase 3 โ€” $15B Primary completion for SKB264 trial (NCT06448312) in Non-Small Cell Lung Cancer
2026-11-15
in 687 days 		NAMS NewAmsterdam Pharma Co N.V. Obicetrapib Trial Phase 3 โ€” $18B Primary completion for Obicetrapib trial (NCT05202509) in Atherosclerotic Cardiovascular D
2026-11-15
in 687 days 		ATOS ATOSSA THERAPEUTICS, INC. (Z)-endoxifen Trial Phase 2 โ€” $18B Primary completion for (Z)-endoxifen trial (NCT05607004) in Breast Neoplasms
2026-11-15
in 687 days 		VXRT Vaxart, Inc. VXA-CoV2-3.1 Trial Phase 2 โ€” $15B Primary completion for VXA-CoV2-3.1 trial (NCT06672055) in SARS-CoV2
2026-11-15
in 687 days 		MNKD MannKind Corporation Basal insulin Trial Phase 2 โ€” $15B Primary completion for Basal insulin trial (NCT07224321) in Type 1 Diabetes Mellitus
2026-11-15
in 687 days 		MNKD MannKind Corporation Technosphere Insulin Trial Phase 3 โ€” $55B Primary completion for Technosphere Insulin trial (NCT07224321) in Type 1 Diabetes Mellitu
2026-11-15
in 687 days 		LLY Eli Lilly and Company LY3938577 Trial Phase 2 โ€” $35B Primary completion for LY3938577 trial (NCT07215312) in Diabetes Mellitus, Type 2
2026-11-15
in 687 days 		LLY Eli Lilly and Company MORF-057 Trial Phase 2 โ€” $18B Primary completion for MORF-057 trial (NCT06226883) in Inflammatory Bowel Diseases
2026-11-15
in 687 days 		NAMS NewAmsterdam Pharma Co N.V. obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks Trial Phase 2 โ€” $18B Primary completion for obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks trial (
2026-11-17
in 689 days 		AZN AstraZeneca PLC Volrustomig Trial Phase 3 โ€” $15B Primary completion for Volrustomig trial (NCT06079671) in Locally Advanced Cervical Cancer
2026-11-19
in 691 days 		RHHBY Roche Holding AG RO7269162 Trial Phase 2 โ€” $15B Primary completion for RO7269162 trial (NCT06402838) in Alzheimer's Disease
2026-11-19
in 691 days 		NVS Novartis AG 225Ac-PSMA-R2 Trial Phase 2 โ€” $15B Primary completion for 225Ac-PSMA-R2 trial (NCT05983198) in Prostate Cancer
2026-11-23
in 695 days 		NVO Novo Nordisk A/S insulin aspart Trial Phase 3 โ€” $50B Primary completion for Insulin aspart trial (NCT07076199) in Diabetes Mellitus, Type 1
2026-11-23
in 695 days 		NVO Novo Nordisk A/S insulin glargine Trial Phase 3 โ€” $50B Primary completion for Insulin glargine trial (NCT07076199) in Diabetes Mellitus, Type 1
2026-11-23
in 695 days 		NVO Novo Nordisk A/S Insulin Icodec Trial Phase 3 โ€” $35B Primary completion for Insulin icodec trial (NCT07076199) in Diabetes Mellitus, Type 1
2026-11-27
in 699 days 		RHHBY Roche Holding AG Semaglutide Trial Phase 2 โ€” $55B Primary completion for RO7795081 trial (NCT07112872) in Type 2 Diabetes Mellitus
2026-11-30
in 702 days 		AZN AstraZeneca PLC Durvalumab Trial Phase 3 โ€” $15B Primary completion for Durvalumab trial (NCT07081633) in Hepatocellular Carcinoma
2026-11-30
in 702 days 		NVSEF NOVARTIS AG Ribociclib Trial Phase 3 โ€” $18B Primary completion for Ribociclib trial (NCT05358249) in KRAS G12C Mutant Solid Tumors
2026-11-30
in 702 days 		BAYRY BAYER BAY2927088_formulation A Trial Phase 2 โ€” $15B Primary completion for BAY2927088_formulation A trial (NCT05099172) in Advanced Non-small
2026-11-30
in 702 days 		VTRS MYLAN MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) Trial Phase 2 โ€” $12B Primary completion for MR-130A-01 contraceptive transdermal patch, containing norelgestrom
2026-11-30
in 702 days 		SNY Sanofi Isatuximab intravenous (IV) Trial Phase 2 โ€” $15B Primary completion for Isatuximab intravenous (IV) trial (NCT05669989) in Plasma Cell Myel
2026-12-01
in 773 days 		SNY Sanofi Itepekimab (SAR440340) Trial Phase 3 โ€” $15B Primary completion for Itepekimab (SAR440340) trial (NCT06208306) in Chronic Obstructive P
2026-12-01
in 773 days 		ALMS ALUMIS INC. ESK-001 Trial Phase 3 โ€” $12B Primary completion for ESK-001 trial (NCT05739435) in Plaque Psoriasis
2026-12-01
in 773 days 		NVO Novo Nordisk A/S NNC0662-0419 Trial Phase 2 โ€” $15B Primary completion for NNC0662-0419 trial (NCT07184632) in Overweight
2026-12-02
in 774 days 		PFE PFIZER Enzalutamide Trial Phase 3 โ€” $18B Primary completion for Enzalutamide trial (NCT06629779) in Metastatic Castration-Resistant
2026-12-03
in 775 days 		ESALY Eisai E2814 Trial Phase 2 โ€” $15B Primary completion for E2814 trial (NCT06602258) in Alzheimer's Disease
2026-12-06
in 778 days 		PFE PFIZER ibuzatrelvir Trial Phase 3 โ€” $15B Primary completion for ibuzatrelvir trial (NCT07013474) in COVID-19 Infection
2026-12-09
in 781 days 		AZN AstraZeneca PLC Capecitabine Trial Phase 3 โ€” $12B Primary completion for Capecitabine trial (NCT07069712) in Gastroesophageal Adenocarcinoma
2026-12-15
in 787 days 		ABBV AbbVie Inc. Tavapadon Trial Phase 3 โ€” $12B Primary completion for Placebo trial (NCT05843643) in Systemic Lupus Erythematosus
2026-12-15
in 787 days 		ABBV AbbVie Inc. Ranibizumab (LUCENTISยฎ) Trial Phase 3 โ€” $15B Primary completion for Ranibizumab (LUCENTISยฎ) trial (NCT04704921) in AMD
2026-12-15
in 787 days 		MDGL Madrigal Pharmaceuticals, Inc. Resmetirom Trial Phase 3 โ€” $12B Primary completion for Resmetirom trial (NCT05500222) in NASH
2026-12-15
in 787 days 		CODX Co-Diagnostics, Inc. SKB264 Trial Phase 3 โ€” $15B Primary completion for SKB264 trial (NCT06711900) in Non-Small Cell Lung Cancer
2026-12-15
in 787 days 		CODX Co-Diagnostics, Inc. pemetrexed Trial Phase 3 โ€” $15B Primary completion for pemetrexed trial (NCT06711900) in Non-Small Cell Lung Cancer
2026-12-15
in 787 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Docetaxel Trial Phase 3 โ€” $15B Primary completion for Docetaxel trial (NCT06382129) in Non-small Cell Lung Cancer
2026-12-15
in 787 days 		NAMS NewAmsterdam Pharma Co N.V. obicetrapib 10 mg + ezetimibe 10 mg FDC daily Trial Phase 3 โ€” $15B Primary completion for obicetrapib 10 mg + ezetimibe 10 mg FDC daily trial (NCT06305559) i
2026-12-15
in 787 days 		LLY Eli Lilly and Company Retatrutide Trial Phase 3 โ€” $25B Primary completion for Retatrutide trial (NCT06662383) in Obesity
2026-12-15
in 787 days 		GILD Gilead Sciences, Inc. Eribulin Mesylate Injection Trial Phase 3 โ€” $15B Primary completion for Sacituzumab Govitecan-hziy trial (NCT04639986) in Metastatic Breast
2026-12-15
in 787 days 		GLSI Greenwich LifeSciences, Inc. GLSI-100 Trial Phase 3 โ€” $18B Primary completion for GLSI-100 trial (NCT05232916) in Breast Cancer
2026-12-15
in 787 days 		GILD Gilead Sciences, Inc. anitocabtagene-autoleucel Trial Phase 2 โ€” $15B Primary completion for anitocabtagene-autoleucel trial (NCT05396885) in Multiple Myeloma
2026-12-15
in 787 days 		VRNA VERONA PHARMA Ensifentrine Trial Phase 3 โ€” $15B Primary completion for Ensifentrine trial (NCT05270525) in COPD
2026-12-15
in 787 days 		JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 Trial Phase 2 โ€” $15B Primary completion for SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 trial (NCT05482568) in A
2026-12-15
in 787 days 		CODX Co-Diagnostics, Inc. BL-M07D1 Trial Phase 2 โ€” $15B Primary completion for BL-M07D1 trial (NCT06131450) in Gynecological Malignancies
2026-12-15
in 787 days 		EIKN Eikon Therapeutics, Inc. Paclitaxel Trial Phase 2 โ€” $18B Primary completion for Paclitaxel trial (NCT06246110) in NSCLC
2026-12-15
in 787 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR GNC-035 Trial Phase 2 โ€” $12B Primary completion for GNC-035 trial (NCT06066203) in Non-hodgkin's Lymphoma
2026-12-15
in 787 days 		ZLAB Zai Lab Limited ZL-1310 Trial Phase 3 โ€” $12B Primary completion for ZL-1310 trial (NCT06885281) in Solid Tumors
2026-12-15
in 787 days 		LLY Eli Lilly and Company Pirtobrutinib Trial Phase 2 โ€” $12B Primary completion for Pirtobrutinib trial (NCT06721013) in Immune Thrombocytopenia (ITP)
2026-12-15
in 787 days 		ALZN Alzamend Neuro, Inc. AL001 Trial Phase 2 โ€” $15B Primary completion for AL001 trial (NCT07540338) in Bipolar I Disorder
2026-12-15
in 787 days 		LLY Eli Lilly and Company LY3457263 Trial Phase 2 โ€” $55B Primary completion for LY3457263 trial (NCT06897475) in Type 2 Diabetes
2026-12-15
in 787 days 		ANRO Alto Neuroscience, Inc. ALTO-203 25 ฮผg Trial Phase 2 โ€” $15B Primary completion for Placebo trial (NCT05922878) in Major Depressive Disorder
2026-12-15
in 787 days 		CODX Co-Diagnostics, Inc. PD-1 Monoclonal Antibody Trial Phase 2 โ€” $15B Primary completion for PD-1 Monoclonal Antibody trial (NCT06008054) in Esophageal Cancer
2026-12-15
in 787 days 		ANRO Alto Neuroscience, Inc. ALTO-300 Trial Phase 2 โ€” $15B Primary completion for ALTO-300 trial (NCT05922878) in Major Depressive Disorder
2026-12-15
in 787 days 		GEHC GE HealthCare Technologies Inc. Regadenoson Trial Phase 2 โ€” $15B Primary completion for Regadenoson trial (NCT04604782) in Myocardial Ischemia
2026-12-18
in 790 days 		ABBV AbbVie Inc. Tavapadon Trial Phase 3 โ€” $12B Primary completion for Placebo trial (NCT03339128) in Irritable Bowel Syndrome
2026-12-23
in 795 days 		SNY Sanofi MRI contrast-enhancing agents Trial Phase 3 โ€” $28B Primary completion for MRI contrast-enhancing agents trial (NCT06141486) in Multiple Scler
2026-12-23
in 795 days 		SNY Sanofi Frexalimab Trial Phase 3 โ€” $15B Primary completion for Frexalimab trial (NCT06141486) in Multiple Sclerosis
2026-12-23
in 795 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT04700124) in Bladder Cancer
2026-12-24
in 796 days 		NVS Novartis AG Ofatumumab approved dose Trial Phase 3 โ€” $12B Primary completion for Ofatumumab approved dose trial (NCT06869785) in Relapsing Multiple
2026-12-25
in 797 days 		NVO Novo Nordisk A/S Semaglutide Trial Phase 3 โ€” $25B Primary completion for Semaglutide trial (NCT03811561) in Diabetes Mellitus, Type 2
2026-12-27
in 799 days 		CNTA Centessa Pharmaceuticals plc epilepsy drug PDUFA NDA โ€” $15B For epilepsy. NDA submitted. AI-extracted from: Praxis tees up another approval filing; Ge
2026-12-30
in 802 days 		CLCS Cell Source, Inc. JointStem Trial Phase 3 โ€” $12B Primary completion for JointStem trial (NCT04368806) in Osteoarthritis, Knee
2026-12-30
in 802 days 		IVA Inventiva S.A. IVA337 Trial Phase 3 โ€” $12B Primary completion for IVA337 trial (NCT04849728) in NASH - Nonalcoholic Steatohepatitis
2026-12-30
in 802 days 		PFE PFIZER ARV-471 (PF-07850327) Trial Phase 3 โ€” $18B Primary completion for ARV-471 (PF-07850327) trial (NCT05909397) in Breast Cancer
2026-12-30
in 802 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR KN035 Trial Phase 2 โ€” $14B Primary completion for KN035 trial (NCT03667170) in Solid Tumor
2026-12-30
in 802 days 		BIO BIO-RAD LABORATORIES, INC. LB1410 Trial Phase 2 โ€” $12B Primary completion for LB1410 trial (NCT06468358) in Solid Tumor
2026-12-30
in 802 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR Docetaxel Trial Phase 3 โ€” $15B Primary completion for Docetaxel trial (NCT05631262) in Selected Subjects With Advanced So
2026-12-30
in 802 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SKB264 Trial Phase 3 โ€” $15B Primary completion for SKB264 trial (NCT05631262) in Selected Subjects With Advanced Solid
2026-12-30
in 802 days 		PFE PFIZER ARV-471 Trial Phase 3 โ€” $12B Primary completion for ARV-471 trial (NCT05573555) in Breast Cancer
2026-12-30
in 802 days 		SLS SELLAS Life Sciences Group, Inc. SLS009 Trial Phase 2 โ€” $12B Primary completion for SLS009 trial (NCT04588922) in Hematologic Malignancies
2026-12-30
in 802 days 		PFE PFIZER Ribociclib Trial Phase 3 โ€” $18B Primary completion for Ribociclib trial (NCT05573555) in Breast Cancer
2026-12-31
in 803 days 		PFE PFIZER Lenalidomide Trial Phase 3 โ€” $15B Primary completion for Lenalidomide trial (NCT04404283) in Diffuse Large B-cell Lymphoma
2026-12-31
in 803 days 		JNGHF Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR SHR-A1811 Trial Phase 3 โ€” $15B Primary completion for SHR-A1811 trial (NCT05424835) in HER2-Positive, Unresectable and/or
2026-12-31
in 803 days 		RHHBY Roche Holding AG Pertuzumab Trial Phase 3 โ€” $18B Primary completion for Pertuzumab trial (NCT02320435) in Solid Tumors
2026-12-31
in 803 days 		RHHBY Roche Holding AG Trastuzumab Trial Phase 3 โ€” $18B Primary completion for Trastuzumab trial (NCT02320435) in Solid Tumors
2026-12-31
in 803 days 		RHHBY Roche Holding AG Optional Endocrine Therapy of Investigator's Choice Trial Phase 3 โ€” $15B Primary completion for Inavolisib trial (NCT05894239) in Metastatic Breast Cancer
2026-12-31
in 803 days 		GOVX GeoVax Labs, Inc. COVID-19 Vaccine Trial Phase 2 โ€” $15B Primary completion for COVID-19 Vaccine trial (NCT04977024) in COVID-19 Infection
2026-12-31
in 803 days 		MRK MERCK MK-1167 Trial Phase 2 โ€” $15B Primary completion for MK-1167 trial (NCT06721156) in Alzheimer Disease
2026-12-31
in 803 days 		JAZZ Jazz Pharmaceuticals plc Zanidatamab Trial Phase 3 โ€” $15B Primary completion for Zanidatamab trial (NCT06695845) in Breast Cancer
2026-12-31
in 803 days 		PFE PFIZER Palbociclib Trial Phase 3 โ€” $18B Primary completion for Palbociclib trial (NCT05226871) in Breast Cancer
2026-12-31
in 803 days 		MRTX Mirati Therapeutics, Inc. Pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT03785249) in Advanced Cancer
2026-12-31
in 803 days 		SUPN SUPERNUS PHARMACEUTICALS, INC. SPN-821 2400 mg Trial Phase 2 โ€” $15B Primary completion for SPN-821 2400 mg trial (NCT07226661) in Major Depressive Disorder (M
2026-12-31
in 803 days 		POCI PRECISION OPTICS CORPORATION, INC. BCMA CAR-T cells Trial Phase 2 โ€” $15B Primary completion for BCMA CAR-T cells trial (NCT04271644) in Multiple Myeloma
2026-12-31
in 803 days 		POCI PRECISION OPTICS CORPORATION, INC. BCMA targeted prime CAR-T cells Trial Phase 2 โ€” $15B Primary completion for BCMA targeted prime CAR-T cells trial (NCT04776330) in Multiple Mye
2026-12-31
in 803 days 		PFE PFIZER Letrozole Trial Phase 3 โ€” $18B Primary completion for Letrozole trial (NCT05226871) in Breast Cancer
2027-01-04
in 9676 days 		MRK MERCK Paclitaxel Trial Phase 3 โ€” $12B Primary completion for Paclitaxel trial (NCT06356311) in Gastroesophageal Cancer
2027-01-04
in 9676 days 		MRK MERCK Supportive care measures Trial Phase 3 โ€” $15B Primary completion for Supportive care measures trial (NCT06356311) in Gastroesophageal Ca
2027-01-07
in 9679 days 		AZN AstraZeneca PLC AZD9829 Trial Phase 2 โ€” $12B Primary completion for AZD9829 trial (NCT06179511) in Hematological Malignancies
2027-01-08
in 9680 days 		SNY Sanofi Itepekimab (SAR440340) Trial Phase 3 โ€” $15B Primary completion for Itepekimab (SAR440340) trial (NCT06834347) in Chronic Rhinosinusiti
2027-01-12
in 9684 days 		MRK MERCK Sacituzumab Govitecan Trial Phase 3 โ€” $15B Primary completion for Sacituzumab Govitecan trial (NCT05609968) in Carcinoma, Non-Small-C
2027-01-14
in 9686 days 		SBFM Sunshine Biopharma Inc. 608 Q2W Trial Phase 3 โ€” $12B Primary completion for Placebo trial (NCT07261644) in Ankylosing Spondylitis
2027-01-14
in 9686 days 		NVO Novo Nordisk A/S UBT251 Trial Phase 2 โ€” $15B Primary completion for UBT251 trial (NCT07395687) in Overweight
2027-01-14
in 9686 days 		REGN Regeneron Pharmaceuticals, Inc. Sarilumab Trial Phase 3 โ€” $15B Primary completion for Sarilumab trial (NCT05125016) in Metastatic Castration-resistant Pr
2027-01-15
in 9687 days 		GSK GSK plc FF/UMEC/VI Trial Phase 3 โ€” $20B Primary completion for FF/UMEC/VI trial (NCT05757102) in Asthma
2027-01-15
in 9687 days 		LLY Eli Lilly and Company Orforglipron Trial Phase 3 โ€” $25B Primary completion for Orforglipron trial (NCT06972472) in Obesity
2027-01-15
in 9687 days 		AMGN Amgen Inc. Ocrelizumab (US) Trial Phase 3 โ€” $10B Primary completion for Ocrelizumab (US) trial (NCT06700343) in Relapsing-remitting Multipl
2027-01-15
in 9687 days 		RCUS Arcus Biosciences, Inc. Quemliclustat Trial Phase 3 โ€” $12B Primary completion for Quemliclustat trial (NCT05329766) in Gastrointestinal Tract Maligna
2027-01-15
in 9687 days 		MPLT MapLight Therapeutics, Inc. ML-007C-MA BID Trial Phase 2 โ€” $12B Primary completion for ML-007C-MA BID trial (NCT07038876) in Schizophrenia
2027-01-15
in 9687 days 		RCUS Arcus Biosciences, Inc. Zimberelimab Trial Phase 3 โ€” $15B Primary completion for Zimberelimab trial (NCT05329766) in Gastrointestinal Tract Malignan
2027-01-17
in 9689 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for pembrolizumab trial (NCT03407144) in Hodgkin Lymphoma
2027-01-21
in 9693 days 		AMGN Amgen Inc. Maridebart cafraglutide Trial Phase 3 โ€” $80B Primary completion for Maridebart cafraglutide trial (NCT06858878) in Type 2 Diabetes Mell
2027-01-25
in 9697 days 		VRTX Vertex Pharmaceuticals Incorporated Suzetrigine Trial Phase 3 โ€” $30B Primary completion for Suzetrigine trial (NCT06696443) in Diabetic Peripheral Neuropathic
2027-01-25
in 9697 days 		PFE PFIZER MET233 and MET097 Trial Phase 2 โ€” $50B Primary completion for MET233 and MET097 trial (NCT06924320) in Obesity and Obesity-relate
2027-01-28
in 9700 days 		AZN AstraZeneca PLC Capecitabine Trial Phase 3 โ€” $12B Primary completion for Capecitabine trial (NCT07069712) in Gastroesophageal Adenocarcinoma
2027-01-31
in 9703 days 		RHHBY Roche Holding AG Ocrelizumab Test Formulation Trial Phase 2 โ€” $28B Primary completion for Ocrelizumab Test Formulation trial (NCT07074886) in Multiple Sclero
2027-01-31
in 9703 days 		CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ-201 Administration Trial Phase 2 โ€” $15B Primary completion for CELZ-201 Administration trial (NCT05626712) in Type 1 Diabetes
2027-02-01
in 9773 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT04241185) in Urinary Bladder Neoplasms
2027-02-05
in 9777 days 		BMY Bristol-Myers Squibb Company Carboplatin Trial Phase 3 โ€” $15B Primary completion for Carboplatin trial (NCT06946797) in Non-Small Cell Lung Cancer
2027-02-05
in 9777 days 		BMY Bristol-Myers Squibb Company Paclitaxel Trial Phase 3 โ€” $12B Primary completion for Paclitaxel trial (NCT06946797) in Non-Small Cell Lung Cancer
2027-02-05
in 9777 days 		BMY Bristol-Myers Squibb Company Pemetrexed Trial Phase 2 โ€” $15B Primary completion for Pemetrexed trial (NCT06946797) in Non-Small Cell Lung Cancer
2027-02-08
in 9780 days 		RHHBY Roche Holding AG RO7795081 Trial Phase 2 โ€” $50B Primary completion for RO7795081 trial (NCT07112872) in Type 2 Diabetes Mellitus
2027-02-08
in 9780 days 		RHHBY Roche Holding AG Semaglutide Trial Phase 2 โ€” $55B Primary completion for Semaglutide trial (NCT07112872) in Type 2 Diabetes Mellitus
2027-02-09
in 9781 days 		REGN Regeneron Pharmaceuticals, Inc. Apixaban Trial Phase 2 โ€” $12B Primary completion for Apixaban trial (NCT07175428) in Atrial Fibrillation (AF)
2027-02-11
in 9783 days 		RHHBY Roche Holding AG Zifibancimig Trial Phase 2 โ€” $10B Primary completion for Zifibancimig trial (NCT04567303) in Macular Degeneration
2027-02-12
in 9784 days 		OCUL Ocular Therapeutix, Inc. AXPAXLI PDUFA NDA โ€” $12B For wet-AMD. NDA submitted. AI-extracted from: Ocular: 'Buy' As AXPAXLI Program For Wet-AM
2027-02-13
in 9785 days 		MRK MERCK Doxorubicin Trial Phase 3 โ€” $18B Primary completion for doxorubicin trial (NCT03407144) in Hodgkin Lymphoma
2027-02-15
in 9787 days 		LLY Eli Lilly and Company Orforglipron Trial Phase 3 โ€” $25B Primary completion for Orforglipron trial (NCT06672549) in Obesity
2027-02-15
in 9787 days 		SBFM Sunshine Biopharma Inc. 610 Trial Phase 3 โ€” $20B Primary completion for 610 trial (NCT06680947) in Asthma
2027-02-15
in 9787 days 		KRYS Krystal Biotech, Inc. KB707 Trial Phase 2 โ€” $10B Primary completion for KB707 trial (NCT06228326) in Lung Cancer, Non-small Cell
2027-02-15
in 9787 days 		ABBV AbbVie Inc. Ravagalimab Trial Phase 2 โ€” $25B Primary completion for Ravagalimab trial (NCT06972446) in Rheumatoid Arthritis
2027-02-15
in 9787 days 		LLY Eli Lilly and Company Brenipatide Trial Phase 2 โ€” $20B Primary completion for Brenipatide trial (NCT07223840) in Smoking
2027-02-20
in 9792 days 		SKBBY Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR SKB518 Trial Phase 2 โ€” $11B Primary completion for SKB518 trial (NCT07019675) in Lung Carcinoma
2027-02-22
in 9794 days 		AZNCF ASTRAZENECA PLC Osimertinib Trial Phase 3 โ€” $15B Primary completion for Osimertinib trial (NCT05629234) in Cancer
2027-02-22
in 9794 days 		NVS Novartis AG Remibrutinib Trial Phase 3 โ€” $12B Primary completion for Remibrutinib trial (NCT06868212) in Chronic Spontaneous Urticaria (
2027-02-23
in 9795 days 		PFE PFIZER Tofacitinib Trial Phase 3 โ€” $25B Primary completion for tofacitinib trial (NCT04624230) in Ulcerative Colitis
2027-02-25
in 9797 days 		UCBJY UCB Brivaracetam Trial Phase 3 โ€” $15B Primary completion for Brivaracetam trial (NCT04666610) in Childhood Absence Epilepsy
2027-02-26
in 9798 days 		AZN AstraZeneca PLC exenatide Trial Phase 3 โ€” $55B Primary completion for Placebo trial (NCT05138133) in Lupus Nephritis
2027-02-26
in 9798 days 		RHHBY Roche Holding AG Rituximab Trial Phase 3 โ€” $25B Primary completion for Rituximab trial (NCT06084936) in Lymphoma
2027-02-26
in 9798 days 		NVS Novartis AG letrozole Trial Phase 3 โ€” $18B Primary completion for Letrozole trial (NCT01872260) in Breast Cancer
2027-02-26
in 9798 days 		NVS Novartis AG BYL719 Trial Phase 2 โ€” $18B Primary completion for BYL719 trial (NCT01872260) in Breast Cancer
2027-02-26
in 9798 days 		NVS Novartis AG Alpelisib Trial Phase 3 โ€” $12B Primary completion for Alpelisib trial (NCT04524000) in Advanced Breast Cancer
2027-02-26
in 9798 days 		RHHBY Roche Holding AG Cevostamab Trial Phase 2 โ€” $15B Primary completion for Cevostamab trial (NCT05535244) in Multiple Myeloma
2027-03-01
in 9873 days 		GSK GSK plc Feladilimab PDUFA Phase 2 โ€” $15B For multiple myeloma. BLA filing. Extracted from SEC filing: 6-K
2027-03-01
in 9873 days 		NVO Novo Nordisk A/S CagriSema (Cagrilintide B and Semaglutide I) Trial Phase 3 โ€” $25B Primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT07011667) in
2027-03-01
in 9873 days 		GENK GEN Restaurant Group, Inc. SUL-238 (1500 mg t.i.d.) film-coated tablets Trial Phase 2 โ€” $12B Primary completion for SUL-238 (1500 mg t.i.d.) film-coated tablets trial (NCT07322887) in
2027-03-04
in 9876 days 		XENE Xenon Pharmaceuticals Inc. Azetukalner PDUFA Phase 3 โ€” $15B For epilepsy. NDA submitted. AI-extracted from: Xenon gets Phase 3 win with epilepsy drug,
2027-03-08
in 9880 days 		MRK MERCK methotrexate Trial Phase 3 โ€” $12B Primary completion for Methotrexate trial (NCT07176390) in Arthritis, Rheumatoid
2027-03-13
in 9885 days 		RYTM RHYTHM PHARMACEUTICALS, INC. Setmelanotide Trial Phase 3 โ€” $15B Primary completion for Setmelanotide trial (NCT06760546) in Hypothalamic Obesity
2027-03-15
in 9887 days 		ADVB Advanced Biomed Inc. [18F]PSMA-1007 Trial Phase 3 โ€” $15B Primary completion for [18F]PSMA-1007 trial (NCT06122584) in Prostate Cancer
2027-03-15
in 9887 days 		VTRS MYLAN Transdermal system containing progestin Trial Phase 3 โ€” $15B Primary completion for Transdermal system containing progestin trial (NCT06672016) in Fema
2027-03-15
in 9887 days 		ABBV AbbVie Inc. Cariprazine Trial Phase 3 โ€” $15B Primary completion for Cariprazine trial (NCT04777357) in Depression
2027-03-15
in 9887 days 		DCPH Deciphera Pharmaceuticals, Inc. Inlexisertib Trial Phase 2 โ€” $15B Primary completion for Inlexisertib trial (NCT05957367) in GIST
2027-03-15
in 9887 days 		LLY Eli Lilly and Company Macupatide Trial Phase 2 โ€” $25B Primary completion for Macupatide trial (NCT07215559) in Obesity
2027-03-15
in 9887 days 		ABBV AbbVie Inc. Paclitaxel Trial Phase 3 โ€” $15B Primary completion for Paclitaxel trial (NCT06632951) in Urothelial Carcinoma
2027-03-15
in 9887 days 		ABBV AbbVie Inc. Docetaxel Trial Phase 3 โ€” $15B Primary completion for Docetaxel trial (NCT06632951) in Urothelial Carcinoma
2027-03-15
in 9887 days 		SPTX Seaport Therapeutics, Inc. SPT-300 Trial Phase 2 โ€” $15B Primary completion for SPT-300 trial (NCT07065240) in Major Depressive Disorder (MDD)
2027-03-15
in 9887 days 		MNKD MannKind Corporation Basal insulin Trial Phase 2 โ€” $15B Primary completion for Technosphere Insulin trial (NCT07224321) in Type 1 Diabetes Mellitu
2027-03-15
in 9887 days 		PCRX Pacira BioSciences, Inc. Enekinragene Inzadenovec (PCRX-201) Trial Phase 2 โ€” $12B Primary completion for Enekinragene Inzadenovec (PCRX-201) trial (NCT06884865) in Osteoart
2027-03-17
in 9889 days 		AZN AstraZeneca PLC AZD9550 Trial Phase 2 โ€” $25B Primary completion for AZD9550 trial (NCT06151964) in Overweight and Obesity
2027-03-18
in 9890 days 		HELP CYBIN INC. CYB003 Trial Phase 3 โ€” $15B Primary completion for CYB003 trial (NCT06793397) in Major Depressive Disorder (MDD)
2027-03-21
in 9893 days 		AZN AstraZeneca PLC Ramucirumab Trial Phase 2 โ€” $15B Primary completion for Ramucirumab trial (NCT07098338) in Non-Small Cell Lung Cancer
2027-03-22
in 9894 days 		MRK MERCK Lenvatinib Trial Phase 3 โ€” $15B Primary completion for Lenvatinib trial (NCT04976634) in Neoplasm Malignant
2027-03-22
in 9894 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT04976634) in Neoplasm Malignant
2027-03-25
in 9897 days 		REGN Regeneron Pharmaceuticals, Inc. Sarilumab Trial Phase 3 โ€” $15B Primary completion for Sarilumab trial (NCT04590326) in Ovarian Cancer
2027-03-28
in 9900 days 		PFE PFIZER PF-07275315 Trial Phase 2 โ€” $20B Primary completion for PF-07275315 trial (NCT06977581) in Asthma
2027-03-31
in 9903 days 		TNGX Tango Therapeutics, Inc. TNG456 Trial Phase 2 โ€” $15B Primary completion for TNG456 trial (NCT06810544) in Non Small Cell Lung Cancer
2027-03-31
in 9903 days 		INVA Vivus VI-0609 Trial Phase 2 โ€” $15B Primary completion for VI-0609 trial (NCT06915246) in Lymphoma
2027-03-31
in 9903 days 		RHHBY Roche Holding AG Englumafusp alfa Trial Phase 2 โ€” $12B Primary completion for Englumafusp alfa trial (NCT04077723) in Lymphoma, Non-Hodgkin
2027-03-31
in 9903 days 		ESALY Eisai BB-1701 Trial Phase 2 โ€” $18B Primary completion for BB-1701 trial (NCT06188559) in Breast Cancer
2027-04-04
in 9976 days 		CFOO China Foods Holdings Ltd. Trastuzumab Pamirtecan (T-Pam, DB-1303, BNT323) PDUFA NDA โ€” $12B For Unresectable or Metastatic HER2-Positive Adult Breast Cancer. BLA accepted. AI-extract
2027-04-06
in 9978 days 		AZN AstraZeneca PLC Olaparib Trial Phase 3 โ€” $12B Primary completion for Olaparib trial (NCT04421963) in Ovarian Cancer
2027-04-06
in 9978 days 		VRTX Vertex Pharmaceuticals Incorporated Suzetrigine Trial Phase 3 โ€” $30B Primary completion for Suzetrigine trial (NCT07231419) in Diabetic Peripheral Neuropathic
2027-04-15
in 9987 days 		ITCI Intra-Cellular Therapies, Inc. Lumateperone Trial Phase 3 โ€” $15B Primary completion for Lumateperone trial (NCT06372964) in Bipolar Depression
2027-04-15
in 9987 days 		LLY Eli Lilly and Company LY3537982 Trial Phase 3 โ€” $15B Primary completion for LY3537982 trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-15
in 9987 days 		LLY Eli Lilly and Company Pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-15
in 9987 days 		LLY Eli Lilly and Company pemetrexed Trial Phase 3 โ€” $15B Primary completion for Pemetrexed trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-15
in 9987 days 		IPIX Innovation Pharmaceuticals Inc. S095018 Trial Phase 2 โ€” $15B Primary completion for S095018 trial (NCT06162572) in Non-small Cell Lung Cancer (NSCLC)
2027-04-15
in 9987 days 		LLY Eli Lilly and Company cisplatin Trial Phase 3 โ€” $15B Primary completion for Cisplatin trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-15
in 9987 days 		KPTI Karyopharm Therapeutics Inc. Bortezomib Trial Phase 3 โ€” $15B Primary completion for Bortezomib trial (NCT02343042) in Multiple Myeloma
2027-04-15
in 9987 days 		KPTI Karyopharm Therapeutics Inc. Dexamethasone Trial Phase 3 โ€” $15B Primary completion for Dexamethasone trial (NCT02343042) in Multiple Myeloma
2027-04-15
in 9987 days 		KPTI Karyopharm Therapeutics Inc. Lenalidomide Trial Phase 2 โ€” $15B Primary completion for Lenalidomide trial (NCT02343042) in Multiple Myeloma
2027-04-15
in 9987 days 		LLY Eli Lilly and Company LY3016859 ISA Trial Phase 2 โ€” $12B Primary completion for LY3016859 ISA trial (NCT05986292) in Osteoarthritis, Knee
2027-04-15
in 9987 days 		LLY Eli Lilly and Company carboplatin Trial Phase 3 โ€” $18B Primary completion for Carboplatin trial (NCT04956640) in Carcinoma, Non-Small-Cell Lung
2027-04-23
in 9995 days 		MRK MERCK pembrolizumab Trial Phase 3 โ€” $15B Primary completion for Pembrolizumab trial (NCT06305767) in Bladder Cancer
2027-04-27
in 9999 days 		AMGN Amgen Inc. Maridebart cafraglutide Trial Phase 3 โ€” $80B Primary completion for Maridebart cafraglutide trial (NCT06987695) in Obesity Disease
2027-04-27
in 9999 days 		NVS Novartis AG GXV813 Trial Phase 2 โ€” $12B Primary completion for GXV813 trial (NCT07467993) in Schizophrenia
2027-04-28
in 10000 days 		PFE PFIZER Tofacitinib Trial Phase 3 โ€” $25B Primary completion for tofacitinib trial (NCT04624230) in Ulcerative Colitis
2027-04-28
in 10000 days 		SNY Sanofi Frexalimab Trial Phase 3 โ€” $15B Primary completion for Frexalimab trial (NCT06111586) in Type 1 Diabetes Mellitus